RNA‐binding motif protein 24 inhibits HBV replication in vivo

Despite the extensive use of effective vaccines and antiviral drugs, chronic hepatitis B virus (HBV) infection continues to pose a serious threat to global public health. Therapies with novel mechanisms of action against HBV are being explored for achieving a functional cure. In this study, five murine models of HBV replication were used to investigate the inhibitory effect of RNA binding motif protein 24 (RBM24) on HBV replication. The findings revealed that RBM24 serves as a host restriction factor and suppresses HBV replication in vivo. The transient overexpression of RBM24 in hydrodynamics‐based mouse models of HBV replication driven by the CMV or HBV promoters suppressed HBV replication. Additionally, the ectopic expression of RBM24 decreased viral accumulation and the levels of HBV covalently closed circular DNA (cccDNA) in an rcccDNA mouse model. The liver‐directed transduction of adeno‐associated viruses (AAV)‐RBM24 mediated the stable hepatic expression of RBM24 in pAAV‐HBV1.2 and HBV/tg mouse models, and markedly reduced the levels of HBV cccDNA and other viral indicators. Altogether, these findings revealed that RBM24 inhibits the replication of HBV in vivo, and RBM24 may be a potential therapeutic target for combating HBV infections.

[1]  A. Rötig,et al.  Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice , 2022, Nature Communications.

[2]  Y. Guan,et al.  DNA Repair Factor Poly(ADP-Ribose) Polymerase 1 Is a Proviral Factor in Hepatitis B Virus Covalently Closed Circular DNA Formation , 2022, Journal of virology.

[3]  E. Gane,et al.  How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? , 2022, Journal of hepatology.

[4]  Xinwen Chen,et al.  Enhanced host immune responses in presence of HCV facilitate HBV clearance in coinfection , 2022, Virologica Sinica.

[5]  Xinwen Chen,et al.  RNA-Binding motif protein 38 (RBM38) mediates HBV pgRNA packaging into the nucleocapsid. , 2022, Antiviral research.

[6]  H. Razavi,et al.  Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[7]  Yuqi Li,et al.  STING signaling activation inhibits HBV replication and attenuates the severity of liver injury and HBV-induced fibrosis , 2021, Cellular & Molecular Immunology.

[8]  Pravindra Kumar,et al.  Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens , 2021, Bioorganic & Medicinal Chemistry.

[9]  Xinwen Chen,et al.  HDAC11 restricts HBV replication through epigenetic repression of cccDNA transcription. , 2019, Antiviral research.

[10]  M. Buti,et al.  Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference , 2019, Hepatology.

[11]  F. Zoulim,et al.  Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. , 2019, Journal of hepatology.

[12]  Anh-Hoa Nguyen,et al.  Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study. , 2019, Journal of hepatology.

[13]  Y. Huang,et al.  Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B , 2019, Journal of viral hepatitis.

[14]  T. Xing,et al.  miRNA‐548ah promotes the replication and expression of hepatitis B virus by targeting histone deacetylase 4 , 2019, Life sciences.

[15]  Xinwen Chen,et al.  RNA-Binding Motif Protein 24 (RBM24) Is Involved in Pregenomic RNA Packaging by Mediating Interaction between Hepatitis B Virus Polymerase and the Epsilon Element , 2019, Journal of Virology.

[16]  Quanxin Long,et al.  SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3‐9 homolog 1 and SET domain containing 1A histone methyltransferases , 2018, Hepatology.

[17]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[18]  Xinwen Chen,et al.  RBM24 stabilizes hepatitis B virus pregenomic RNA but inhibits core protein translation by targeting the terminal redundancy sequence , 2018, Emerging Microbes & Infections.

[19]  Hao Chang,et al.  Recombinant covalently closed circular DNA of hepatitis B virus induces long‐term viral persistence with chronic hepatitis in a mouse model , 2018, Hepatology.

[20]  Mengji Lu,et al.  The dose of HBV genome contained plasmid has a great impact on HBV persistence in hydrodynamic injection mouse model , 2017, Virology Journal.

[21]  Jiangxia Liu,et al.  PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation , 2017, Hepatology.

[22]  T. Block,et al.  Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA , 2017, PLoS pathogens.

[23]  R. Mikolajczyk,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[24]  C. Seeger,et al.  Molecular biology of hepatitis B virus infection. , 2015, Virology.

[25]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[26]  Yueqiu Gao,et al.  Recombinant Covalently Closed Circular Hepatitis B Virus DNA Induces Prolonged Viral Persistence in Immunocompetent Mice , 2014, Journal of Virology.

[27]  Jiming Zhang,et al.  Inhibition of Hepatitis B Virus Replication by the Host Zinc Finger Antiviral Protein , 2013, PLoS pathogens.

[28]  D. Vassilopoulos,et al.  Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. , 2012, Gastroenterology.

[29]  K. High,et al.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges , 2011, Nature Reviews Genetics.

[30]  M. Levrero,et al.  Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function , 2009, Proceedings of the National Academy of Sciences.

[31]  Jianming Hu,et al.  Hepatitis B virus–cell interactions and pathogenesis , 2008, Journal of cellular physiology.

[32]  M. Nassal.  Hepatitis B viruses: reverse transcription a different way. , 2008, Virus research.

[33]  Dexi Liu,et al.  Hydrodynamic gene delivery: its principles and applications. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  E. Engvall,et al.  ELISA (Enzyme‐Linked Immunosorbent Assay) , 2002 .

[35]  Li-Ling Wu,et al.  Hydrodynamic HBV Transfection Mouse Model. , 2017, Methods in molecular biology.